12-[5-[bis[(2-methylpropan-2-yl)oxycarbonylamino]methylideneamino]-3-methyl-2-[3-[5-[N-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]-2-methylsulfanylthiophen-3-yl]sulfonylphenyl]anilino]-12-oxododecanoic acid | 821773-43-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 12-[5-[bis[(2-methylpropan-2-yl)oxycarbonylamino]methylideneamino]-3-methyl-2-[3-[5-[N-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]-2-methylsulfanylthiophen-3-yl]sulfonylphenyl]anilino]-12-oxododecanoic acid
• CAS: 821773-43-7
• 化学式: C₄₇H₆₆N₆O₁₁S₃
• 分子量: 987.273
• InChiKey: QIPGGHRZMBSBPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.7
• 重原子数：
  67
• 可旋转键数：
  26
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.51
• 拓扑面积：
  316
• 氢给体数：
  5
• 氢受体数：
  13

反应信息

• 作为产物：
  描述：

  11-乙氧羰基十二烷酰氯 在 甲醇 、 铁粉 、 氯化铵 、 溶剂黄146 、 三乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 3.0h， 生成 12-[5-[bis[(2-methylpropan-2-yl)oxycarbonylamino]methylideneamino]-3-methyl-2-[3-[5-[N-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]-2-methylsulfanylthiophen-3-yl]sulfonylphenyl]anilino]-12-oxododecanoic acid
  参考文献：
  名称：

  Design and synthesis of polyethylene glycol-modified biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s

  摘要：

  Complement C1s protease inhibitors have potential utility in the treatment of diseases associated with activation of the classical complement pathway such as humorally mediated graft rejection, ischemia-reperfusion injury (IRI), vascular leak syndrome, and acute respiratory distress syndrome (ARDS). The utility of biphenylsulfonyl-thiophene-carboxamidine small-molecule C1s inhibitors are limited by their poor in vivo pharmacokinetic properties. Pegylation of a potent analog has provided compounds with good potency and good in vivo pharmacokinetic properties. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.030

文献信息

• US7482376B2
  申请人：——

  公开号：US7482376B2

  公开（公告）日：2009-01-27
• Design and synthesis of polyethylene glycol-modified biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s
  作者：Nalin L. Subasinghe、Ehab Khalil、Jeremy M. Travins、Farah Ali、Shelley K. Ballentine、Heather R. Hufnagel、Wenxi Pan、Kristi Leonard、Roger F. Bone、Richard M. Soll、Carl S. Crysler、Nisha Ninan、Jennifer Kirkpatrick、Michael X. Kolpak、Karen A. Diloreto、Stephen H. Eisennagel、Norman D. Huebert、Christopher J. Molloy、Bruce E. Tomczuk、Michael D. Gaul

  DOI：10.1016/j.bmcl.2012.06.030

  日期：2012.8

  Complement C1s protease inhibitors have potential utility in the treatment of diseases associated with activation of the classical complement pathway such as humorally mediated graft rejection, ischemia-reperfusion injury (IRI), vascular leak syndrome, and acute respiratory distress syndrome (ARDS). The utility of biphenylsulfonyl-thiophene-carboxamidine small-molecule C1s inhibitors are limited by their poor in vivo pharmacokinetic properties. Pegylation of a potent analog has provided compounds with good potency and good in vivo pharmacokinetic properties. (C) 2012 Elsevier Ltd. All rights reserved.